Silence on price rise

Despite increasing concern among pharmacy and healthcare groups over the rising costs of Panadol Osteo, there is as yet no indication from the Federal Government that a change of plan is under consideration.

Panadol Osteo was one of a raft of medicines delisted from the PBS from 1 January as part of the government’s PBS sustainability package.

While the medicines were meant to be available at an OTC price that is comparable to the PBS price, Panadol Osteo has had a rapid price rise, with further hikes in store once existing stock is cleared, as manufacturer GSK says it will have to raise the price by up to 50%.